Key result
High-dose interleukin-2 therapy was associated with alveolar edema in 21%, interstitial edema in 53%, and pleural effusions in 42% of patients during the first 5 days of therapy.
Population
19 patients undergoing the priming course of high-dose IL-2 therapy for metastatic melanoma and renal cell…
Design
Case_series
Follow-up
first 5 days of therapy
Authors
Loading...
Radiographic IL-2 toxicity is common yet self-limited; extends early descriptions of vascular leak but leaves open relevance to current regimens.
Observational (n=19)
High-dose IL-2 therapy frequently causes self-limited, increased-permeability pulmonary edema and pleural effusions, with a risk of fatal myocardial injury.
Mann et al. (1990) conducted an observational in Metastatic melanoma and renal cell carcinoma (n=19). High-dose interleukin-2 (IL-2) therapy was evaluated on Prevalence and patterns of pulmonary edema and pleural effusions. High-dose interleukin-2 therapy was associated with alveolar edema in 21%, interstitial edema in 53%, and pleural effusions in 42% of patients during the first 5 days of therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: